Table 1. Baseline characteristics of 14 studies for Bayesian network meta-analysis by cancer type.
| First author, year | Study ID | Region | Trial phase | Total No. | Safety analysis No | Arm | Treatment (median follow-up time, months) | CTCAE version |
|---|---|---|---|---|---|---|---|---|
| Breast cancer | ||||||||
| Advanced HER2-negative breast cancer and a germline BRCA1/2 mutation | ||||||||
| Jennifer K. Litton, 2018 | EMBRACA | MN | III | 431 | 286 | 1 | Talazoparib 1 mg once daily (11.2) | 4.03 |
| 126 | 2 | ICC (capecitabine, eribulin, gemcitabine, or vinorelbine every 3 weeks) (11.2) | ||||||
| Mark Robson, 2017 | OlympiAD | MN | III | 302 | 205 | 1 | Olaparib 300 mg twice daily (14.5) | 4.0 |
| 91 | 2 | ICC (capecitabine, eribulin, or vinorelbine every 3 weeks) (14.1) | ||||||
| Ovarian cancer | ||||||||
| Measurable or evaluable high-grade serous or endometrioid platinum-sensitive recurrent ovarian cancer | ||||||||
| Mansoor Raza Mirza, 2019 | NSGO-AVANOVA2 | MN | II | 97 | 48 | 1 | Niraparib 300mg once daily plus bevacizumab 15mg/kg once every 3 weeks (16.9) | 4.0 |
| 49 | 2 | Niraparib 300mg once daily (16.9) | ||||||
| Joyce F. Liu, 2019* | NCT01116648 | USA | II | 90 | 46 | 1 | Olaparib 400 mg twice daily (46.0) | 4.0 |
| 44 | 2 | Olaparib 200 mg twice daily and cediranib 30 mg daily (46.0) | ||||||
| Robert L. Coleman, 2017 | ARIEL3 | MN | III | 564 | 372 | 1 | Rucaparib 600 mg twice daily (NR) | 4.03 |
| 189 | 2 | Placebo (NR) | ||||||
| Ovarian cancer that recurred within 12 months of prior platinum therapy and with confirmed germline BRCA1 or BRCA2 mutations | ||||||||
| Stan B. Kaye, 2011† | NCT00628251 | MN | II | 97 | 32 | 1 | Olaparib 200 mg twice daily (NR) | 3.0 |
| 32 | 2 | Olaparib 400 mg twice daily (NR) | ||||||
| 32 | 3 | Pegylated liposomal doxorubicin 50 mg/m2 intravenously every 28 days (NR) | ||||||
| Advanced ovarian cancer following response on front-line platinum-based chemotherapy | ||||||||
| A. González-Martín, 2019 | PRIMA | MN | III | 733 | 484 | 1 | Niraparib 300 mg once daily (13.8) | 4.03 |
| 244 | 2 | Placebo (13.8) | ||||||
| High-grade serous platinum-sensitive, recurrent ovarian cancer | ||||||||
| Mansoor R. Mirza, 2016 | ENGOT-OV16/NOVA | MN | III | 553 | 367 | 1 | Niraparib 300 mg once daily (16.9) | 4.02 |
| 179 | 2 | Placebo (16.9) | ||||||
| Jonathan Ledermann, 2012 | Study 19 NCT00753545 | MN | II | 265 | 136 | 1 | Olaparib 400 mg twice daily (78.0) | 3.0 |
| 128 | 2 | Placebo (78.0) | ||||||
| Newly diagnosed advanced high-grade serous or endometrioid platinum-sensitive ovarian cancer with BRCA1 or BRCA2 mutations | ||||||||
| K. Moore, 2018 | SOLO1 | MN | III | 391 | 260 | 1 | Olaparib 300 mg twice daily (40.7) | 4.0 |
| 130 | 2 | Placebo (41.2) | ||||||
| Advanced high-grade serous or endometrioid platinum-sensitive ovarian cancer with BRCA1 or BRCA2 mutations | ||||||||
| Eric Pujade-Lauraine, 2017 | SOLO2 | MN | III | 295 | 195 | 1 | Olaparib 300 mg twice daily (22.1) | 4.0 |
| 99 | 2 | Placebo (22.2) | ||||||
| Richard T. Penson, 2020 | SOLO3 | MN | III | 266 | 178 | 1 | Olaparib 300 mg twice daily (13.8) | 4.0 |
| 76 | 2 | ICC (pegylated liposomal doxorubicin, paclitaxel, gemcitabine, or topotecan) (3.9) | ||||||
| Prostate cancer | ||||||||
| Metastatic castration-resistant prostate cancer with DDR gene aberrations | ||||||||
| Joaquin Mateo, 2020† | TOPARP-B | UK | II | 98 | 49 | 1 | Olaparib 400 mg twice daily (24.8) | 4.02 |
| 49 | 2 | Olaparib 300 mg twice daily (24.8) | ||||||
| Pancreatic cancer | ||||||||
| Metastatic pancreatic adenocarcinoma with germline BRCA mutations that had not progressed during first-line platinum-based chemotherapy | ||||||||
| Talia Golan, 2019 | POLO | MN | III | 154 | 91 | 1 | Olaparib 300 mg twice daily (9.1) | 4.0 |
| 60 | 2 | Placebo (3.8) | ||||||
*, the study was excluded from the dose and drug based network meta-analysis; †, grade ≥3 adverse events were not available in the study by Stan B. Kaye-2011/Joaquin Mateo-2020, so serious adverse events were used. CTCAE, Common Terminology Criteria for Adverse Events; MN, multinational; NR, not reported; ICC, investigator’s choice chemotherapy.